Blueprint Medicines Corporation (BPMC)
| Market Cap | 6.24B |
| Revenue (ttm) | 828.10M |
| Net Income (ttm) | 340.15M |
| Shares Out | 58.41M |
| EPS (ttm) | 5.81 |
| PE Ratio | 18.35 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 189,179 |
| Open | 108.89 |
| Previous Close | 109.47 |
| Day's Range | 106.45 - 109.47 |
| 52-Week Range | 79.08 - 125.61 |
| Beta | 0.71 |
| Analysts | Buy |
| Price Target | 119.00 (+11.6%) |
| Est. Earnings Date | Oct 28, 2021 |
About BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available...
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is 119.00, which is an increase of 11.62% from the latest price.
News
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 4, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on August 1, 2021, the Compensation Committee of Blueprint Medicines' Board ...
Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues
Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.
Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -5.09% and -4.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines: Q2 Earnings Insights
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 18.42% year over year to ($1.86), which were in line w...
Blueprint Medicines Reports Second Quarter 2021 Financial Results
CAMBRIDGE, Mass., July 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the second quarter ended June 30, 2021.
MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development
HOUSTON and CAMBRIDGE, Mass., July 28, 2021 /PRNewswire/ -- The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation (NASDAQ: BPMC) today announced a three-year strategic re...
Will Blueprint Medicines (BPMC) Report Negative Q2 Earnings? What You Should Know
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
CAMBRIDGE, Mass., July 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,...
3 Biotech Stocks Ready for Big Breakthroughs Like Biogen
This could be a breakthrough year for these three biotech stocks, resulting in massive gains for their stockholders similar to Biogen. The post 3 Biotech Stocks Ready for Big Breakthroughs Like Biogen a...
Blueprint Medicines (BPMC) Gets FDA Nod for Ayvakyt in SM
The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
CAMBRIDGE, Mass., June 16, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) for th...
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 4, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on June 1, 2021, the Compensation Committee of Blueprint Medicines' Board of...
Blueprint Medicines to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.
Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Pa...
CAMBRIDGE, Mass., May 19, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the presentation of updated Phase 1/2 ARROW trial data demonstrating durable clinical benefi...
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass., May 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Percy Carter, MBA, Ph.D.
Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag
Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.
Recap: Blueprint Medicines Q1 Earnings
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 18.48% over the past year to ($1.72), which beat the e...
Blueprint Medicines Reports First Quarter 2021 Financial Results
CAMBRIDGE, Mass., April 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2021.
Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
CAMBRIDGE, Mass., April 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.
3 Magic Formula Health Care Stock Picks
If you want to enhance your likelihood to beat the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.
1 Cancer Stock to Buy and Hold for the Next Decade
Blueprint Medicines is setting itself up to become the leader in precision oncology.
Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021
CAMBRIDGE, Mass., April 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that multiple presentations across the company's leading systemic mastocytosis (SM) progra...
Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual M...
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced data from multiple poster presentations highlighting the breadth of the company's precisio...